首页|期刊导航|中国药业|京津冀生物医药临床研究实力分析

京津冀生物医药临床研究实力分析OA

Analysis of Clinical Research Capacity in Biomedicine in the Beijing-Tianjin-Hebei Region

中文摘要英文摘要

目的 分析京津冀生物医药领域临床研究实力.方法 通过ClinicalTrials.gov数据库,检索 2015-2024 年京津冀生物医药领域临床研究数据,采用文献计量学方法分析三地该领域的临床研究注册规模、研究设计、实施特征及合作情况.结果 临床研究注册规模方面,京津冀共注册生物医药领域临床研究 8722 项,其中北京数量(7530 项)远超天津(2363 项)、河北(1027 项),且三地均呈逐年增长态势.研究设计与实施特征方面,研究类型以干预性研究为主(90.98%),其中Ⅲ期药物临床试验占比较高(23.86%);干预类型以药物为主(83.73%),但北京器械和其他类型研究占比(16.03%、2.34%)高于天津(8.08%、1.95%)、河北(11.30%、0.78%).研究多未设性别限制(91.01%),受试者主要集中于成人/老年人(79.67%);招募阶段研究占 30.22%,已公布研究结果的研究占 8.35%.临床研究合作情况方面,单机构临床研究、国内合作临床研究和国际合作临床研究占比分别为 55.26%、27.81%和 16.92%,各类合作临床研究均以北京参与度最高.京津冀在国内合作临床研究中均与广东和江苏等地保持较高水平的合作,在国际合作中均以美国、西班牙、韩国为主要合作对象,但合作格局存在一定差异.结论 京津冀生物医药领域临床研究数量持续增长,呈资源集聚与协同发展并行的特征,未来应推动京津优质临床资源跨区域共享,确立差异化功能定位,深化国内协同与国际合作的双向格局.

Objective To analyze the clinical research capacity in the biomedical field in the Beijing-Tianjin-Hebei region.Methods The clinical research data of the biomedical field in the Beijing-Tianjin-Hebei region from 2015 to 2024 were collected through ClinicalTrials.gov database.Bibliometric methods were used to analyze the registation scale,research design,implementation characteristics,and cooperation of clinical research in the this fieled among the three regions.Results In terms of the registation scale of clinical research,a total of 8 722 clinical studies in the biomedical field were registered in the Beijing-Tianjin-Hebei region,of which the number in Beijing(7 530 studies)was much higher than that in Tianjin(2 363 studies)and Hebei(1 027 studies),all showing a growth trend.In terms of research design and implementation characteristics,the type of research was mainly intervention research(90.98%);the proportion of phase Ⅲ drug clinical trials was relatively high(23.86%);the intervention type was mainly drugs(83.73%),but the proportion of instruments and other types of research in Beijing(16.03%,2.34%)was higher than those in Tianjin(8.08%,1.95%)and Hebei(11.30%,0.78%).Most studies did not set gender restrictions(91.01%),and the majority of participants were adults or elderly populations(79.67%);the proportion of research at the recruitment stage was 30.22%,and the proportion of research results published was 8.35%.In terms of cooperation of clinical research,the proportion of single-institution clinical research,domestic cooperative clinical research and international cooperative clinical research were 55.26%,27.81%and 16.92%,respectively,and the participation in different types of cooperative clinical research in Beijing were highest.In domestic cooperative clinical research,the Beijing-Tianjin-Hebei region maintained a high level of cooperation with Guangdong,Jiangsu and other provinces;in international cooperation,the United States,Spain and South Korea were the main partners,though there were certain differences in the cooperation patterns among the three regions.Conclusions The number of clinical research in the biomedical field of the Beijing-Tianjin-Hebei region continues to grow,with the characteristics of resource agglomeration and collaborative development.In the future,we should promote the cross-regional sharing of high-quality clinical resources in Beijing-Tianjin,establish differentiated functional positioning,and deepen the dual framework of domestic collaboration and international cooperation.

卢岩;张婷;陈佩璇;王瑛昊;杨君;欧阳昭连

北京协和医学院·中国医学科学院医学信息研究所·图书馆,北京 100020北京协和医学院·中国医学科学院医学信息研究所·图书馆,北京 100020吉林大学公共卫生学院,吉林 长春 130012吉林大学公共卫生学院,吉林 长春 130012吉林大学公共卫生学院,吉林 长春 130012北京协和医学院·中国医学科学院医学信息研究所·图书馆,北京 100020

医药卫生

京津冀生物医药临床研究区域协同文献计量学

Beijing-Tianjin-Hebei regionbiomedicineclinical researchregional collaborationbibliometric

《中国药业》 2026 (4)

1-9,9

北京市社会科学基金项目(重点项目)[24JCB024].

10.3969/j.issn.1006-4931.2026.04.001

评论